CORDIS
EU research results

CORDIS

English EN

Nanoscale Functionalities for Targeted Drug Delivery of Biopharmaceutics

Objective

The Integrated Project NanoBioPharmaceutics aims at the development of innovative multidisciplinary approaches for the design, synthesis and evaluation of functionalised nano-carriers and nano-particle-based micro-carriers for the treatment of various diseases based on targeted, controlled delivery of therapeutic peptides and proteins (biopharmaceutics).

More specifically, the present IP aims at the following scientific and technological objectives:
1. Design, synthesis and functionalization of novel nano-carriers and nano-particle-based micro-carriers for targeted delivery of P/P drugs via oral, pulmonary and Blood Brain Barrier (BBB) crossing administration routes.
2. Toxicological screening of the nano-carriers and investigation of the release profile of P/P drug under various environmental conditions and the assessment of the biocompatibility and biodegradability of the new formulations.
3. Novel pulmonary P/P carriers with improved delivery features to overcome the administration difficulties and increase efficiency of protein delivery to the deep lung.
4. Oral nano-particulate P/P carrier systems capable of adhering to the gastrointestinal mucosa and also displaying protective and permeation enhancing properties.
5. Establishment of an in vitro model for the assessment of nano-carriers permeability through the Blood Brain Barrier (BBB).

The present IP integrates the scientific activities and complementary skills of researchers coming from 13 EU countries and the state of Israel, in an attempt to ensure breakthrough advances in novel biopharmaceutics delivery systems. The Consortium consists of 12 University departments, 6 research institutes, 6 SMEs and 3 large industries. An efficient management scheme has been established to ensure the fulfilment of the IP's scientific, technological and exploitation objectives.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

DECHEMA GESELLSCHAFT FUER CHEMISCHE TECHNIK UND BIOTECHNOLOGIE E.V.

Address

Theodor-Heuss-Allee 25
Frankfurt Am Main

Germany

Administrative Contact

Kurt WAGEMANN (Dr)

Participants (26)

Sort alphabetically

Expand all

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

Switzerland

UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ

Germany

MEDIZINISCHE UNIVERSITAET GRAZ

Austria

TEL AVIV UNIVERSITY

Israel

UNIVERSITE DE LIEGE

Belgium

UNIVERSITAET INNSBRUCK

Austria

INSTITUT QUIMIC DE SARRIA

Spain

UNIVERSITEIT TWENTE

Netherlands

CHALMERS TEKNISKA HOEGSKOLA AKTIEBOLAG

Sweden

DEUTSCHES WOLLFORSCHUNGSINSTITUT AN DER RWTH AACHEN E.V.

Germany

UNIVERSITEIT MAASTRICHT

Netherlands

CENTRUM BADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH POLSKIEJ AKADEMII NAUK

Poland

JOANNEUM RESEARCH FORSCHUNGSGESELLSCHAFT MBH

Austria

KEMIJSKI INSTITUT LJUBLJANA SLOVENIJA

Slovenia

NATIONAL CENTRE FOR SCIENTIFIC RESEARCH "DEMOKRITOS"

Greece

LEK FARMACEVTSKA DRUZBA DD - LEK PHARMACEUTICALS

Slovenia

MAGNAMEDICS GMBH

Germany

REGULON SA

Greece

THIOMATRIX FORSCHUNGS- UND BERATUNGS GMBH

Austria

LIPOXEN TECHNOLOGIES LIMITED

United Kingdom

NOVO NORDISK A/S

Denmark

APLAGEN GMBH

Germany

GLAXOSMITHKLINE BIOLOGICALS S.A.

Belgium

Centre for Research and Technology Hellas

Greece

SUSTECH GMBH AND CO. KG

Germany

UNIVERSITA DEGLI STUDI DI TRIESTE

Italy

Project information

Grant agreement ID: 26723

  • Start date

    1 October 2006

  • End date

    30 September 2010

Funded under:

FP6-NMP

  • Overall budget:

    € 11 099 662

  • EU contribution

    € 7 997 720

Coordinated by:

DECHEMA GESELLSCHAFT FUER CHEMISCHE TECHNIK UND BIOTECHNOLOGIE E.V.

Germany